Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1845

Sort by

Sort Order Select

Journal Articles

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Hanna Kirchhoff, Uemran Karsli, Caroline Schoenherr, Karin Battmer, Sergej Erschow, Steven R. Talbot, Doris Steinemann, Michael Heuser, Olaf Heidenreich, Denise Hilfiker-Kleiner, Arnold Ganser, Matthias Eder, Michaela Scherr

Blood (2021) 137 (19): 2657–2661.

https://doi.org/10.1182/blood.2020008544

Published: 2021

Includes: Supplemental data

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

Blood (2020) 135 (26): 2365–2374.

https://doi.org/10.1182/blood.2019003877

Published: 2020

Includes: Supplemental data

Journal Articles

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Mahmoud Hallal, BSc, MSc, Sophie Braga-Lagache, MSc, Jovana Jankovic, Rémy Bruggmann, PhD, Ramanjaneyulu Allam, PhD MSc, BSc, Mario P. Tschan, PhD, Cédric Simillion, PhD, Manfred Heller, PhD, Nicolas Bonadies, MD

Blood (2019) 134 (Supplement_1): 2079.

https://doi.org/10.1182/blood-2019-122337

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Lamya Garabet, Pal André Holme, PhDMD, Bernadette Darne, Abderrahim Khelif, Tor Henrik Anderson Tvedt, MD, Marc Michel, Waleed Ghanima, MD PhD

Blood (2019) 134 (Supplement_1): 4892.

https://doi.org/10.1182/blood-2019-126974

Published: 2019

Journal Articles

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Jordan K Schaefer, MD, Yun Li, PhD, Xiaowen Kong, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Sahana R Shankar, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 787.

https://doi.org/10.1182/blood-2019-122526

Published: 2019

Journal Articles

A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism

Jordan K Schaefer, MD, Josh Errickson, PhD, Xiaokui Gu, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 788.

https://doi.org/10.1182/blood-2019-123067

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD

Blood (2019) 134 (Supplement_1): 1003.

https://doi.org/10.1182/blood-2019-130767

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood (2019) 134 (Supplement_1): 810.

https://doi.org/10.1182/blood-2019-126192

Published: 2019

Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1371.

https://doi.org/10.1182/blood-2019-130427

Published: 2019

Journal Articles

No Improvement in Survival for T-PLL Patients over the Last Two Decades

Matthew J Cross, MBBS, BSc, Monica Else, Ricardo Morilla, Mark Edward Ethell, MD, Michael Potter, MD, Dima El-Sharkawi, Sunil Iyengar, MBBS, FRCPath, PhD, Claire E. Dearden, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 1552.

https://doi.org/10.1182/blood-2019-122094

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 1374.

https://doi.org/10.1182/blood-2019-130033

Published: 2019

Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 1530.

https://doi.org/10.1182/blood-2019-125681

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

No Improvement in Survival for T-PLL Patients over the Last Two Decades

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only